• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于定量测定小鼠血浆和组织相关基质中KRAS抑制剂阿达格拉西布的高效液相色谱-串联质谱法的开发与验证。

Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.

作者信息

Retmana Irene A, Loos Nancy H C, Schinkel Alfred H, Beijnen Jos H, Sparidans Rolf W

机构信息

Division of Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.

Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

出版信息

Biomed Chromatogr. 2023 Nov;37(11):e5720. doi: 10.1002/bmc.5720. Epub 2023 Aug 19.

DOI:10.1002/bmc.5720
PMID:37596864
Abstract

We developed and validated an assay utilizing a liquid chromatography-tandem mass spectrometry technique to quantify the KRAS inhibitor adagrasib in mouse plasma and seven tissue-related matrices. The straightforward protein precipitation technique was selected to extract adagrasib and the internal standard salinomycin from the matrices. Gradient elution of acetonitrile and water modified with 0.5% (v/v) ammonium hydroxide and 0.02% (v/v) acetic acid on a C column at a flow rate of 0.6 ml/min was applied to separate the analytes. Both adagrasib and salinomycin were detected with a triple quadrupole mass spectrometer with positive electrospray ionization in a selected reaction monitoring mode. A linear calibration range of 2-2,000 ng/ml of adagrasib was demonstrated during the validation. In addition, the reported precision values (intra- and inter-day) were between 3.5 and 14.9%, while the accuracy values were 85.5-111.0% for all tested levels in all investigated matrices. Adagrasib in mouse plasma was reported to have good stability at room temperature, while adagrasib in tissue-related matrices was stable on ice for up to 4 h (matrix dependent). Finally, this method was successfully applied to determine the pharmacokinetic profile and tissue distribution of adagrasib in wild-type mice.

摘要

我们开发并验证了一种利用液相色谱 - 串联质谱技术来定量测定小鼠血浆和七种组织相关基质中KRAS抑制剂阿达格拉西布的分析方法。选用简单的蛋白沉淀技术从基质中提取阿达格拉西布和内标沙利霉素。在C柱上,以0.6 ml/min的流速,用0.5%(v/v)氢氧化铵和0.02%(v/v)乙酸改性的乙腈和水进行梯度洗脱,以分离分析物。阿达格拉西布和沙利霉素均采用三重四极杆质谱仪,在正电喷雾电离的选择反应监测模式下进行检测。在验证过程中,阿达格拉西布的线性校准范围为2 - 2,000 ng/ml。此外,在所有研究基质的所有测试水平下,报告的精密度值(日内和日间)在3.5%至14.9%之间,而准确度值为85.5% - 111.0%。据报道,小鼠血浆中的阿达格拉西布在室温下具有良好的稳定性,而组织相关基质中的阿达格拉西布在冰上最多可稳定4小时(取决于基质)。最后,该方法成功应用于测定野生型小鼠中阿达格拉西布的药代动力学特征和组织分布。

相似文献

1
Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.一种用于定量测定小鼠血浆和组织相关基质中KRAS抑制剂阿达格拉西布的高效液相色谱-串联质谱法的开发与验证。
Biomed Chromatogr. 2023 Nov;37(11):e5720. doi: 10.1002/bmc.5720. Epub 2023 Aug 19.
2
Validated LC-MS/MS method for simultaneous quantification of KRAS inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.用于同时定量检测 KRAS 抑制剂索托拉西布及其主要循环代谢物(M24)在小鼠基质中的经验证的 LC-MS/MS 方法及其在小鼠药代动力学研究中的应用。
J Pharm Biomed Anal. 2023 Oct 25;235:115612. doi: 10.1016/j.jpba.2023.115612. Epub 2023 Jul 31.
3
Development and validation of an LC-MS/MS method for the quantification of KRAS inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study.一种用于定量测定几种小鼠基质中KRAS抑制剂opnurasib的液相色谱-串联质谱法的开发与验证及其在小鼠药代动力学研究中的应用
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Jan 1;1232:123964. doi: 10.1016/j.jchromb.2023.123964. Epub 2023 Dec 9.
4
Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.采用液相色谱-串联质谱法检测小鼠血浆和组织匀浆中的 KRAS 抑制剂索托拉西布。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jun 1;1174:122718. doi: 10.1016/j.jchromb.2021.122718. Epub 2021 Apr 20.
5
Application of newly developed and validated LC-MS/MS method for pharmacokinetic study of adagrasib and pembrolizumab simultaneously in rat plasma.新型 LC-MS/MS 法在大鼠血浆中同时进行阿达格拉西布和帕博利珠单抗药代动力学研究的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Jul 1;1241:124171. doi: 10.1016/j.jchromb.2024.124171. Epub 2024 May 31.
6
Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs.经过验证的扩展多重液相色谱-串联质谱分析法,用于定量测定人血浆中的阿达格拉西布和索托拉西布,以及另外四种小分子抑制剂。
J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Dec 1;1231:123918. doi: 10.1016/j.jchromb.2023.123918. Epub 2023 Nov 7.
7
Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.采用液相色谱-串联质谱法定量检测小鼠血浆和组织匀浆中的 FGFR4 抑制剂 BLU-554。
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:116-123. doi: 10.1016/j.jchromb.2019.02.017. Epub 2019 Feb 16.
8
Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.使用液相色谱-串联质谱法测定新一代 ROS1/TRK/ALK 抑制剂 repotrectinib 在小鼠血浆和组织匀浆中的生物分析测定法。
J Chromatogr B Analyt Technol Biomed Life Sci. 2020 May 1;1144:122098. doi: 10.1016/j.jchromb.2020.122098. Epub 2020 Apr 1.
9
Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates.建立并验证一种 LC-MS/MS 检测方法,用于定量检测小鼠血浆和组织匀浆中的 cintirorgon(LYC-55716)。
J Pharm Biomed Anal. 2022 Jan 5;207:114421. doi: 10.1016/j.jpba.2021.114421. Epub 2021 Oct 7.
10
Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.建立并验证了 UPLC-MS/MS 法同时测定人血浆/血清中 6 种酪氨酸激酶抑制剂及其 2 种活性代谢物浓度的方法,用于治疗药物监测。
J Pharm Biomed Anal. 2022 Mar 20;211:114562. doi: 10.1016/j.jpba.2021.114562. Epub 2021 Dec 30.